Caption: L-R – Mr. Dominic Carolan, CEO of NIBRT, and Dr. Mark Barrett, Co-Founder & CEO of APC Ltd.
 
The Applied Process Company (APC) and the National Institute for Bioprocessing Research & Training (NIBRT), have signed a strategic partnership agreement to provide their respective client bases with increased access to research, development and analytical services across their complementary biopharmaceutical services.
 
APC have been utilizing NIBRT’s expertise to complement its own analytical development services in certain areas for several years. This agreement sees the companies deepen that relationship to offer their combined client base access to the broader complementary services. This collaborative arrangement will enable both companies to act as a point of referral for clients requiring expert process development and biopharmaceutical services.
 
Leveraging APC’s process development and optimization services through application of its state-of-the-art process analytical technology (PAT), coupled to NIBRT’s extensive biopharmaceutical services and knowledge in single use, pilot plant and bioanalytical capabilities, the partnership will better serve the complex needs of the shared client base.
 
“We welcome this logical extension to our current relationship with NIBRT and recognize the value of their biopharmaceutical services, complementing our own in-house bioprocess development and optimization technologies, which have recently benefited from multimillion-euro investment,” said David Downey, chief commercial officer, APC. “This mutually beneficial arrangement will further increase our capabilities in delivering complex process development solutions to our global client base.”  
 
Killian O’Driscoll, director of projects, NIBRT, said, “Our global client base has complex bioanalytical characterization and process development requirements to support their development of their innovative therapeutics. We’re delighted to announce the further strengthening of our partnership with APC to assist clients design, develop and characterize their biological processes and products. This will help optimize the cost and time to develop and launch these medicines to the highest quality standards.”